14 studies found for:    HCV | Open Studies | Interventional Studies | United States, Florida | Adult | Phase 2, 3, 4
Show Display Options
Rank Status Study
1 Recruiting A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Condition: Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
Age Groups: Adult / Senior
2 Recruiting Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Conditions: Hepatitis C Infection;   Viruses;   Hepatocellular Carcinoma;   Hepatitis, Viral, Human;   Liver Cirrhosis
Intervention: Biological: Civacir® 10%
Age Groups: Adult / Senior
3 Recruiting A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 (HIV-1) Coinfection
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Interventions: Drug: ABT-450/r/ABT-267;   Drug: ABT-333;   Drug: Ribavirin (RBV)
Age Groups: Adult / Senior
4 Recruiting A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study
Condition: Hepatitis C
Interventions: Drug: ABT-450/ritonavir;   Drug: ABT-333;   Drug: ABT-267
Age Groups: Adult / Senior
5 Recruiting Safety and Efficacy of MK-5172 + MK-8742 in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
Condition: Hepatitis C Virus
Interventions: Drug: MK-5172;   Drug: MK-8742;   Drug: Placebo to MK-5172;   Drug: Placebo to MK-8742
Age Groups: Adult / Senior
6 Not yet recruiting An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
Condition: Hepatitits C
Interventions: Drug: Simeprevir;   Drug: Sofosbuvir;   Drug: Ribavirin
Age Groups: Adult / Senior
7 Recruiting Study of Efficacy and Safety of MK-5172/MK-8742 Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, 5, and 6 (MK-5172-060)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: MK-5172 100mg/MK-8742 50 mg fixed-dose combination;   Drug: Placebo to MK-5172 + MK-8742 fixed-dose combination
Age Groups: Adult / Senior
8 Recruiting Study of Efficacy and Safety of MK-5172 + MK-8742 With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, 5, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
Condition: Hepatitis C Infection
Interventions: Drug: MK-5172 + MK-8742;   Drug: RBV
Age Groups: Adult / Senior
9 Recruiting Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: Sofosbuvir;   Drug: RBV
Age Groups: Adult / Senior
10 Recruiting A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
Conditions: Liver Fibrosis;   Hepatic Fibrosis
Intervention: Drug: IDN-6556
Age Groups: Adult / Senior
11 Recruiting Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV
Condition: Chronic Hepatitis C Infection
Interventions: Biological: Pegylated Interferon Lambda-1a;   Drug: Daclatasvir (DCV);   Drug: Ribasphere (RBV)
Age Groups: Adult / Senior
12 Recruiting Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
Condition: Hepatitis C
Interventions: Drug: BZF961;   Drug: Ritonavir;   Drug: Placebo
Age Groups: Child / Adult / Senior
13 Recruiting Sofosbuvir Plus Ribavirin in Subjects With HCV Infection and Renal Insufficiency
Condition: HCV Infection
Interventions: Drug: Sofosbuvir;   Drug: RBV
Age Groups: Adult / Senior
14 Recruiting An Efficacy and Safety Study of MK-5172 + MK-8742 in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus (C-EDGE COINFECTION) (MK-5172-061)
Condition: Chronic Hepatitis C
Intervention: Drug: MK-5172 100 mg/MK-8742 50 mg fixed-dose combination tablets
Age Groups: Adult / Senior

Indicates status has not been verified in more than two years